We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-13.06%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.87B
AUM Growth
-$516M
Cap. Flow
-$33.5M
Cap. Flow %
-1.79%
Top 10 Hldgs %
48.99%
Holding
144
New
7
Increased
8
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$45.3M
2
FATE icon
Fate Therapeutics
FATE
+$16.6M
3
CYTK icon
Cytokinetics
CYTK
+$11.1M
4
SNTI icon
Senti Biosciences Holdings
SNTI
+$4.46M
5
WVE icon
Wave Life Sciences
WVE
+$3.85M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$60.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$18.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
5
BLU
BELLUS Health Inc.
BLU
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.18%
2 Consumer Discretionary 5.28%
3 Financials 0.87%
4 Consumer Staples 0.28%
5 Industrials 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KA
126
DELISTED
Kineta, Inc. Common Stock
KA
$396K 0.02%
31,056
– –
CLF icon
127
Cleveland-Cliffs
CLF
$6.49B
$384K 0.02%
+25,000
New +$598K
UNG icon
128
United States Natural Gas Fund
UNG
$450M
$380K 0.02%
+5,000
New +$516K
APLT
129
DELISTED
Applied Therapeutics
APLT
$379K 0.02%
400,000
– –
SPRO icon
130
Spero Therapeutics
SPRO
$68.9M
$371K 0.02%
500,000
– –
BBWI icon
131
Bath & Body Works
BBWI
$3.97B
$337K 0.02%
+12,500
New +$543K
SGTX
132
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$229K 0.01%
21,231
– –
CDTX
133
DELISTED
Cidara Therapeutics
CDTX
$110K 0.01%
11,234
– –
ATXS
134
DELISTED
Astria Therapeutics
ATXS
$100K 0.01%
33,333
– –
KLDO
135
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$31K ﹤0.01%
500,500
– –
APLS
136
DELISTED
Apellis Pharmaceuticals
APLS
– –
-200,000
Closed -$10.2M
DNA icon
137
Ginkgo Bioworks
DNA
$498M
– –
-1,250
Closed -$202K
IMCR icon
138
Immunocore
IMCR
$1.7B
– –
-200,000
Closed -$5.98M
INTC icon
139
CALL
Intel
INTC
$413B
– –
-300,000
Closed -$14.9M
PTGX icon
140
Protagonist Therapeutics
PTGX
$8.55B
– –
-800,100
Closed -$18.9M
SAGE
141
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-250,000
Closed -$8.28M
TGTX icon
142
TG Therapeutics
TGTX
$8.19B
– –
-800,000
Closed -$7.61M
XP icon
143
XP
XP
$8.43B
– –
-35,000
Closed -$1.05M
FMTX
144
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-1,000,000
Closed -$9.3M
2 3 4 5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2022 Portfolio in Review

As of Q2 2022, Artal Group held 144 positions worth $1.87B, down 22% from $2.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Artal Group's Q2 2022 filing shows 7 new, 8 increased, 8 reduced and 9 closed positions. Its largest new stake was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M. The largest sale was argenx, an estimated $60.4M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Artal Group's largest Q2 2022 buy was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M.
  • Artal Group added most to Scholar Rock in Q2 2022, an estimated $45.3M increase.
  • Artal Group's biggest Q2 2022 reduction was argenx, cutting an estimated $60.4M.
  • Artal Group fully exited Protagonist Therapeutics in Q2 2022, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 49% of its $1.87B portfolio in Q2 2022.
  • Artal Group opened 7 new positions and closed 9 in Q2 2022.
  • Artal Group's portfolio value fell 22% quarter-over-quarter to $1.87B.

Based on Artal Group's 13F filing for Q2 2022, filed 11 Aug 2022.